NCT05324501: MAGIC-G1

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

Terminated Phase 1 Last updated 10 February 2025

What this trial tests

Phase 1 trial testing MTX110 in Recurrent Glioblastoma in 4 participants. Terminated before completion.

Timeline

19 October 2022

Primary endpoint
10 September 2024

10 September 2024

Quick facts

Lead sponsor	Biodexa Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	19 October 2022
Primary completion	10 September 2024
Estimated completion	10 September 2024
Sites	2 locations across United States

Drugs / interventions tested

• MTX110 — full drug profile →
• Programmable pump and catheter system

Conditions studied

• Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

Biodexa Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
   Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
2. Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease.
   Pedder JH, Sonabend AM, Cearns MD, Michael BD, et al · · 2025 · cited 35× · PMID 39862873 · DOI 10.1016/s1474-4422(24)00476-9
3. Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma.
   Mokarram N, Case A, Hossainy NN, Lyon JG, et al · · 2025 · cited 17× · PMID 39790893 · DOI 10.1038/s43246-024-00721-y
4. Unveiling the enigma of the blood-brain barrier in glioblastoma: current advances from preclinical and clinical studies.
   Ahmed MH, Canney M, Carpentier A, Thanou M, et al · · 2023 · cited 15× · PMID 37681417 · DOI 10.1097/cco.0000000000000990
5. Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review.
   Meleiro M, Henrique R. · · 2025 · cited 9× · PMID 40565099 · DOI 10.3390/ijms26125634
6. H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.
   Nonnenbroich LF, Bouchal SM, Millesi E, Rechberger JS, et al · · 2024 · cited 9× · PMID 38994974 · DOI 10.3390/cells13131122
7. 7aaRGD - a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas.
   Ellert-Miklaszewska A, Pilanc P, Poleszak K, Roura AJ, et al · · 2025 · cited 8× · PMID 40281508 · DOI 10.1186/s13046-025-03393-9
8. Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment.
   Giantini-Larsen AM, Pandey A, Garton ALA, Rampichini M, et al · · 2025 · cited 8× · PMID 39877748 · DOI 10.1093/noajnl/vdae201